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Activation of the Met kinase confers acquired drug resistance
in FGFR-targeted lung cancer therapy
S-M Kim1,6, H Kim1,6, MR Yun1, HN Kang1, K-H Pyo1, HJ Park1, JM Lee1, HM Choi1, P Ellinghaus2, M Ocker2, S Paik3,4, HR Kim5,7
and BC Cho5,7
Aberrant ﬁbroblast growth factor receptor (FGFR) activation/expression is a common feature in lung cancer (LC). In this study, we
evaluated the antitumor activity of and the mechanisms underlying acquired resistance to two potent selective FGFR inhibitors,
AZD4547 and BAY116387, in LC cell lines. The antitumor activity of AZD4547 and BAY1163877 was screened in 24 LC cell lines,
including 5 with FGFR1 ampliﬁcation. Two cell lines containing FGFR1 ampliﬁcations, H1581 and DMS114, were sensitive to FGFR
inhibitors (IC50o250 nM). Clones of FGFR1-ampliﬁed H1581 cells resistant to AZD4547 or BAY116387 (H1581AR and H1581BR cells,
respectively) were established. Receptor tyrosine kinase (RTK) array and immunoblotting analyses showed strong overexpression
and activation of Met in H1581AR/BR cells, compared with that in the parental cells. Gene set enrichment analysis against the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database showed that cytokine–cytokine receptor interaction pathways were
signiﬁcantly enriched in H1581AR/BR cells, with Met contributing signiﬁcantly to the core enrichment. Genomic DNA quantitative
PCR and ﬂuorescent in situ hybridization analyses showed MET ampliﬁcation in H1581AR, but not in H1581BR, cells. Met
ampliﬁcation drives acquired resistance to AZD4547 in H1581AR cells by activating ErbB3. Combination treatment with FGFR
inhibitors and an anaplastic lymphoma kinase (ALK)/Met inhibitor, crizotinib, or Met-speciﬁc short interfering RNA (siRNA)
synergistically inhibited cell proliferation in both H1581AR and H1581BR cells. Conversely, ectopic expression of Met in H1581 cells
conferred resistance to AZD4547 and BAY1163877. Acquired resistance to FGFR inhibitors not only altered cellular morphology, but
also promoted migration and invasion of resistant clones, in part by inducing epithelial-to-mesenchymal transition. Taken together,
our data suggest that Met activation is sufﬁcient to bypass dependency on FGFR signaling. Concurrent inhibition of the Met and
FGFR pathways may have synergistic clinical beneﬁts when targeting FGFR-dependent LC.
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INTRODUCTION
Lung cancer (LC) is the leading cause of cancer-related mortality
worldwide.1 Recently, there has been considerable advances of
molecularly-targeted therapies in LC patients; epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including
geﬁtinib, erlotinib and afatinib, are utilized in patients with EGFR
mutations, while the anaplastic lymphoma kinase (ALK) inhibitor,
crizotinib, is employed in those with ALK rearrangement.2 One of
the newly recognized molecular targets in LC is FGFR. Our groups
and others have already reported FGFR1 ampliﬁcation in
squamous cell carcinoma, a major histologic subtype of LC, at a
frequency of 13–22%.3–6
Fibroblast growth factors receptor (FGFR) gene ampliﬁcation
and overexpression is a common alteration and a potential drug
target in LC.7 Aberrant FGF signaling can promote tumor
development by directly driving cancer cell survival, motility,
invasiveness, proliferation, epithelial-to-mesenchymal transition
(EMT) and angiogenesis.8 Activation of FGF signaling leads to
phosphorylation of the bound ﬁbroblast growth factor receptor
substrate 2 (FRS2) and downstream activation of Ras/Raf/MAPK
(mitogen-activated protein kinase), phosphoinositide 3-kinase
(PI3K)/AKT and Janus kinase/signal transducer and activator of
transcription (STAT) pathways.9
A number of FGFR-targeted agents are currently being
developed in LC harboring FGFR alterations. The TKIs targeting
the ATP-binding site of FGFRs can be classiﬁed into two different
types; multi-target FGFR-TKIs such as PD173074, dovitinib and
ponatinib, and highly-selective FGFR inhibitors such as AZD4547,
BGJ398, LY287445 and BAY1163877.9 AZD4547 is a highly active
pan-FGFR selective inhibitor that was shown to block FGFR
signaling and proliferation in cancer cell lines with deregulated
FGFR expression.10 Recently, a phase Ib trial (NCT00979134)
assessing the efﬁcacy and safety of AZD4547 in advanced
squamous cell LC harboring FGFR1 ampliﬁcation reported overall
response rate of 8%.11 BAY1163877 selectively inhibits FGFR1–3
kinase activity, phosphorylation of downstream signaling mole-
cules and proliferation of various cancer cell lines.12 A phase I
clinical trial (NCT01976741) is underway to test the safety and
preliminary antitumor activity of BAY1163877.13
All effective molecularly-targeted cancer therapies are ham-
pered by acquired drug resistance. Reactivation of the target
through a secondary mutation, activation of upstream or
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downstream effectors and/or activation of a bypass oncoprotein
have been implicated in acquired drug resistance.14 The bypass
resistance mechanism results in the activation of a critical
downstream signaling effector through a parallel mechanism that
is indifferent to the kinase-directed therapy, which has been well
described in EGFR-mutant LC.14 Here, aberrant reactivation of
PI3K/AKT signaling in the presence of geﬁtinib (an EGFR-TKI) can
occur as a result of Met activation through either MET ampliﬁca-
tion or by its ligand hepatocyte growth factor.15,16 Notably, MET
ampliﬁcation causes resistance to geﬁtinib by driving ErbB3-
dependent activation of PI3K.17 In addition to drug resistance, Met
activation promotes cancer progression, metastasis, cancer cell
migration and angiogenesis.15
Recent reports have suggested a signaling crosstalk between
FGFR and Met. In Met-dependent cell lines such as MKN45 (gastric
cancer) and EBC-1 (LC), FGFR is a key regulator of resistance to a
Met-targeting antibody.18 In acute myeloid leukemia, FGFR1
activity is required for the compensatory upregulation of
hepatocyte growth factor in response to Met inhibition.19
Furthermore, hepatocyte growth factor secretion compensates
for cancer cell growth inhibition by BGJ398, a selective FGFR
inhibitor.20
In this study, we evaluated the activity of selective FGFR
inhibitors (AZD4547 and BAY116387) and the mechanisms of
acquired resistance to these agents in LC. We established an
acquired resistance model in vitro, in which an FGFR-TKI-sensitive
cell line, H1581, was subjected to long-term treatment with
AZD4547 and BAY1163877. We conﬁrmed activation of the Met
pathway in cells that had acquired resistance to AZD4547 and
BAY1163877 (H1581AR and H1581BR). We provide evidence in
support of the hypothesis that Met activation is sufﬁcient to
bypass dependency on FGFR signaling. Our data suggest that
concurrent inhibition of these two pathways may be desirable
when targeting FGFR-dependent LC.
RESULTS
Sensitivity to AZD4547 and BAY1163877 in LC cell lines
The antitumor activity of AZD4547 and BAY1163877, of which
chemical structures were shown in Supplementary Figure 1a, was
screened in 24 LC cell lines. Five of the twenty-four cell lines were
reported to harbor FGFR1 ampliﬁcation (H1581, DMS114, H1703,
H520 and HCC95).21 The full panel of LC cell lines, ranked from the
most to the least sensitive to AZD4547 and BAY1163877 based on
inhibition of cell proliferation, with the information of FGFR1 gene
copy number and mRNA expression is shown in Supplementary
Table 1. Of the 24 cell lines, 2 FGFR1-ampliﬁed LC cell lines, H1581
and DMS114, showed extreme sensitivity to AZD4547 and
BAY1163877 (GI50 values ranging from 36 to 244 nM). All other
cell lines were relatively resistant to AZD4547 and BAY1163877,
with GI50 values ranging from 1.5 to 410 μM (Supplementary
Table 1). H1581 and DMS114 showed sensitivity to FGFRi, whereas
H1703, H520 and HCC95 showed resistance. Furthermore, H1581
and DMS114 cells do not have Met expression, whereas H1703,
H520 and HCC95 cells do not show Met expression
(Supplementary Figure 1b).
First, we tested whether there is any difference in the
downstream signaling between sensitive (H1581 and DMS114)
and resistant (H1703, H520 and HCC95) cell lines. Compared with
the resistant cell lines, immunoblotting analysis of lysates from
sensitive cell lines showed increased phosphorylation of FRS2α
and phospholipase C (PLC)-γ, two major substrates of the FGFR
kinase, but decreased phosphorylation of STAT3 (Supplementary
Figure 1c). Overall, sensitive cell lines expressed high mRNA and
protein level of FGFR1 in the presence of FGFR1 ampliﬁcation
(Supplementary Table 1, Supplementary Figure 1c).
Importantly, phosphorylation of extracellular signal-regulated
kinase (ERK)1/2 was signiﬁcantly suppressed upon FGFR-TKI
treatment in sensitive cells, suggesting that phosphorylated
p-ERK1/2 may be a pharmacodynamic marker of downstream
FGFR signaling (Supplementary Figure 1d). Phosphorylation of AKT
is inhibited in DMS114, but not in H1581. In contrast, there was no
effect of AZD4547 and BAY1163877 on p-ERK1/2 or p-AKT levels in
the three resistant cells. Collectively, these data suggest that high
basal level of FRS2α/PLC-γ and/or FGFR inhibition-induced ERK1/2
suppression may account for the sensitivity to AZD4547 or
BAY1163877 in LC cells.
Establishment of AZD4547- and BAY1163877-resistant cell lines
derived from H1581 cells
To explore the potential mechanisms of acquired resistance to
selective FGFR-TKIs, we established drug-resistant cell lines by
treating H1581 cells with stepwise increasing doses (up to 1 μM) of
AZD4547 and BAY1163877 for ~ 6 months. We generated
independent AZD4547- and BAY1163877-resistant cell lines
derived from the highly-sensitive parental H1581 cells (H1581P).
These resistant cell lines were designated H1581AR (AZD4547-
resistant) and H1581BR (BAY1163877-resistant) cells, and subse-
quently maintained in media containing 1 μM AZD4547 or
BAY1163877, respectively. AZD4547 and BAY1163877 dose-
response curves of drug-resistant cell lines and H1581 cells
conﬁrm the acquisition of resistance to these drugs (Figures 1a
and b). H1581AR cells exhibited higher resistance to AZD4547,
with greater than 180-fold higher GI50 than H1581P cells
(GI50 = 6.462 ± 0.172 μM). H1581BR cells showed 100-fold higher
resistance to BAY1163877 (GI50 = 3.986 ± 0.050 μM). Consistent
with these data, treatment with AZD4547 and BAY1163877
resulted in a signiﬁcant decrease in colonies formed by H1581P
cells, but not by H1581AR and BR cells (Figure 1b). Interestingly,
remarkable morphological changes were noted in H1581AR and
H1581BR cells. The spindle-like ﬁbroblastic phenotype, character-
istic of H1581P cells, was markedly attenuated in H1581AR and
H1581BR cells, indicating loss of cell-to-cell connections in the
resistant cell lines (Figure 1c). After treatment with AZD4547 or
BAY1163877, no changes in p-ERK and p-AKT levels were
detectable in H1581AR and BR cells (Figure 1d).
Activation of Met in AZD4547- and BAY1163877-resistant cells
Next, we sought to identify potential mechanisms of acquired
resistance to FGFR-TKIs in H1581AR and H1581BR cells. Receptor
tyrosine kinase (RTK) array and immunoblotting analyses demon-
strated strong overexpression and activation of Met in H1581AR
and H1581BR cells, compared with the nearly-undetectable
expression in the parental cells (Figures 2a and b). The basal level
of Met overexpression/activation in H1581BR cells was lower than
that observed in H1581AR cells. Consistent with the RTK array
data, ErbB3 phosphorylation was markedly elevated in H1581AR
cells, compared with that in H1581P and H1581BR cells. In
H1581AR and H1581BR cells, we also observed phosphorylated
ERK and AKT, two downstream signaling transducers of the Met
pathway (Figure 2b).
Next, we tested whether strong overexpression and activation
of Met in H1581AR and H1581BR is associated with increased
mRNA expression and/or gene copy number of Met. Here, we
used the EBC-1 cell line, in which MET is reported to be
ampliﬁed,22 as the positive control. All the resistant cells, including
those with acquired (H1581AR, H1581BR) and intrinsic (H2170,
H1703, H520, HCC95) resistance to FGFR-TKIs, expressed higher
levels of Met mRNA, compared with that in H1581P cells
(Figure 2c). Interestingly, despite Met activation, H1581BR cells
did not harbor MET copy number gain (2.54) (Figure 2d).
Consistent with quantitative real-time PCR results, H1581AR, but
not H1581BR, showed marked MET gene ampliﬁcation by
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ﬂuorescence in situ hybridization (FISH) (49 copies per cell;
Figure 2e). These ﬁndings suggest that stronger Met over-
expression/activation driven by MET ampliﬁcation might result in
higher level of drug resistance in H1581AR cells, compared with
H1581BR cell (180-fold resistance to AZD4547 in H1581AR vs 100-
fold resistance to BAY1163877 in H1581BR).
Next, H1581P, H1581AR and H1581BR cells were subjected to
genome-wide gene expression proﬁling using cDNA microarray
(Supplementary Table 2). The gene set enrichment analysis (GSEA)
against Kyoto Encyclopedia of Genes and Genomes (KEGG)
database (http://www.genome.jp/kegg/) identiﬁed four pathways
(‘Axon guidance’, ‘Adherens junction’, ‘Focal adhesion’ and
‘Cytokine–cytokine receptor interaction’) that were signiﬁcantly
enriched, with Met contributing signiﬁcantly to the core enrich-
ment, in H1581AR and H1581BR cells, compared with H1581P cells
(Figure 2f, Supplementary Tables 3 and 4).
To further examine the role of Met overexpression and
activation in acquired resistance to FGFR-TKIs, we infected
H1581P cells with lentivirus+ harboring a construct encoding
GFP-tagged Met or the control plasmid carrying GFP alone.
Ectopic expression of Met signiﬁcantly induced resistance to
AZD4547 and BAY1163877 in MTT assays (Figure 3a). Furthermore,
Met overexpression induced activation of downstream ERK1/2 and
AKT, which could not be abrogated by AZD4547 or BAY1163877
treatment (Figure 3b). Taken together, these data suggest that
Met activation is responsible for the acquisition of acquired
resistance to FGFR-TKIs in H1581P.
Met-dependent ErbB3/PI3K signaling in H1581AR, but not in
H1581BR cells
MET ampliﬁcation leads to geﬁtinib resistance in LC by activating
ErbB3-dependent activation of PI3K.17 Given that ErbB3 phosphor-
ylation was markedly elevated in MET-ampliﬁed H1581AR cells,
but not in H1581BR cells (Figures 2a and b), we therefore
hypothesized that acquired resistance to AZD4547 in H1581AR
might involve sustained signaling via ErbB3. The GSEA of gene
expression proﬁles revealed that the ERBB signaling pathway was
signiﬁcantly enriched, with ERBB3 contributing signiﬁcantly to the
core enrichment, in H1581AR cells, compared with H1581BR and
H1581P cells (Figure 4a, Supplementary Table 5). Inhibition of Met
by crizotinib, an ALK/MET TKI, or siMET fully suppressed ErbB3 and
AKT phosphorylation, which suggests that Met can trigger the
activation of ErbB3/PI3K signaling in H1581AR and H1581BR cells
(Supplementary Figures 2a and b). Interestingly, downregulation
of ErbB3 by an ErbB3-speciﬁc short interfering RNA (siRNA) led to
Figure 1. Establishment of H1581 cells resistant to the FGFR-TKIs AZD4547 and BAY1163877. (a) H1581P, H1581AR and H1581BR cells were
treated with AZD4547 and BAY1163877 at the indicated concentrations, and viable cells were measured after 72 h of treatment.
(b) Clonogenic assays of H1581P, H1581AR and H1581BR cells were treated with AZD4547 or BAY1163877 (1 μM) for 10 days. Data shown are
the mean± s.d. of three independent trials. ***Po0.001; signiﬁcantly different from vehicle control. (c) H1581P, H1581AR and H1581BR cells
were treated with a dose escalation of AZD4547 and BAY1163877 for 2 h and cell extracts were immunoblotted to detect the indicated
proteins. c/w, cells/well; DMSO, dimethyl sulfoxide; AZD, AZD4547; BAY, BAY1163877.
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substantial inhibition of AKT phosphorylation in H1581AR, but not
in H1581BR cells, supporting the role of ErbB3 in mediating PI3K/
AKT activation in MET-ampliﬁed H1581AR cells (Figure 4b). To
conﬁrm the validation ﬁndings for ErbB3, we treated H1581 cells
with NRG1 (ligand to ErbB3) and H1581AR cells with AZD8931
(panHER inhibitor) and Met overexpressing cells (EBC-1 cell line)
with ErbB3 siRNA (Supplementary Figures 2c–e). However, there
was no change of resistance to FGFR-TKIs and unavailing. These
ﬁndings also might suggest that there exist different mechanisms
by which PI3K/AKT becomes activated in the two resistant cells.
To investigate how Met activates PI3K/AKT signaling in the two
resistant cells, immunoprecipitation assays were performed. In
H1581AR and H1581BR cells, ErbB3 coprecipitated with Met and
vice versa and, as expected, both interactions were not disrupted
by AZD4547 or BAY1163877 (Figure 4c). However, compared with
H1581P and H1581BR, the association of ErbB3 with the p85
regulatory subunit of PI3K was greatly enhanced in H1581AR cells
and vice versa (Figure 4d, Supplementary Figure 2c). The
association of p85 with ErbB3 was effectively blocked by crizotinib
or combination of crizotinib and AZD4547 in H1581AR cells. These
observation suggest that Met may mediate transphosphorylation
of ErbB3, which creates binding sites for PI3K, in H1581AR cells.
Taken together, these data suggest that MET ampliﬁcation
activates PI3K/AKT signaling through ErbB3 in H1581AR cells,
whereas Met overexpression directly activates PI3K/AKT in
H1581BR cells.
Enhanced invasion, migration and EMT in H1581AR and H1581BR
cells
Given the fact that Met activation triggers enhanced invasion and
metastasis of tumor cells,23 we further investigated whether
constitutive Met activation in H1581AR and H1581BR cells resulted
in upregulation of invasion and migration potentials of these
resistant cells. H1581AR and H1581BR cells displayed signiﬁcant
enhancement of invasive and migratory potentials, compared with
H1581P cells (Figures 5a and b). Immunoblotting analysis of the
EMT markers indicated that H1581AR and H1581BR cells showed
Figure 2. Met is upregulated in H1581AR and H1581BR cells. (a) p-RTK array analysis shows that H1581P, H1581AR and H1581BR cells maintain
phosphorylation of Met in the presence of AZD4547 and BAY1163877. H1581P, H1581AR and H1581BR cell lysates were hybridized to a p-RTK
array. Hybridization signals at the corners serve as controls. (b) H1581P and resistant cells were treated with 0.1 μM AZD4547 or BAY1163877
for 2 h. Cell extracts were immunoblotted to detect the indicated proteins. A Taqman assay was used to determine (c) mRNA expression and
(d) DNA copy numbers of MET. (e) MET ampliﬁcation in tumor cells as shown by FISH. There are increased copies of the orange red signal
(probe binding to MET) compared with the green signal (CEP8, control chromosome enumeration probe). Data shown in (c and d) are the
mean± s.d. of three independent trials. (f) A GSEA plot of KEGG cytokine–cytokine receptor interaction pathway showed signiﬁcant
enrichment in H1581AR and H1581BR vs H1581P (left panel). Heat map representation of the top 25 deregulated genes in H1581AR/BR cells vs
H1581 (right panel). Previously identiﬁed gene sets (available at molecular signature database; MSigDB, C2; www.broadinstitute.org/gsea/)
were screened to identify those that are differentially enriched in H1581AR/H1581BR cells vs H1581P by analyzing relative expressions using
GSEA methods.29
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higher expression of N-cadherin and vimentin, but lower expression
of E-cadherin, compared with the H1581P (Figure 5c). Taken
together, our data suggest that acquisition of acquired resistance to
FGFR-TKIs not only leads to morphological changes, but also
promotes migration and invasion of cells, in part by inducing EMT.
Combined inhibition of FGFR and Met signaling to overcome
acquired resistance to FGFR-TKIs
To determine whether combined inhibition of Met signaling
overcomes the acquired resistance to FGFR-TKIs, we tested the
effects of combined treatment of crizotinib or siMET with FGFR-TKIs
Figure 3. Overexpressed Met enhances resistance in H1581P cells. (a) H1581P cells were infected with lentivirus harboring a construct
encoding GFP-tagged Met or the control plasmid carrying GFP alone. After lentivirus infection, cells were treated with the FGFR-TKIs at the
indicated concentrations. Cells were infected as above with increasing amounts of lentivirus and treated with FGFR-TKIs. (b) Immunoblotting
analysis for the indicated proteins.
Figure 4. Activation of Met is a key determinant of mechanistic differences in difference types of FGFR-TKI-resistant cells. (a) GSEA plot
showing the upregulated expression of previously known ErbB3-associated gene sets in H1581 acquired resistance cells, including genes that
are commonly upregulated in H1581AR cell lines (‘KEGG_ERBB_SIGNALING_PATHWAY’). (b) H1581P, H1581AR and H1581BR cells were
transfected with control siRNA or ErbB3-speciﬁc siRNA as described in Materials and methods. (c) Met/ErbB3 complex formation was evaluated
by immunoprecipitation analysis. All cells were treated with 0.1 μM of each of the indicated FGFR-TKIs. (d) Met or ErbB3 and PI3K p85 subunit
complex formation was evaluated using co-immunoprecipitation analysis. All cells were treated with 0.1 μM of each of the indicated FGFR-TKIs
and 0.2 μM crizotinib. All cell extracts were immunoblotted to detect the indicated proteins.
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on cell viability. The combination of FGFR-TKIs with crizotinib or
siMet synergistically inhibited cell proliferation in both H1581AR
and H1581BR cells (Figure 6a, Supplementary Figure 3a). Similar
data were seen in a clonogenic assay. Consistent with these data,
combined inhibition of Met and FGFR signaling effectively
suppressed ERK1/2 and AKT activation, compared with inhibition
of either pathway alone (Figure 6b, Supplementary Figure 3b).
DISCUSSION
In our study, we evaluated in vitro antitumor activity and
pharmacodynamic effects of selective FGFR-TKIs in a panel of
LC. We found that two FGFR1-ampliﬁed LC cells with high mRNA
and protein expression of FGFR1 were sensitive to FGFR-TKIs and
pharmacodynamic inhibition of p-ERK1/2 may be responsible for
the sensitivity to these agents. Importantly, we herein reported,
Figure 5. H1581-derived drug-resistant cells demonstrate metastatic phenotype. (a) Cell invasion assays (using QCM ECMatrix) were carried
out. The percentages of invasion were quantitated by assessing the percentage of stained invasive cells. **Po0.01; ###Po0.001; signiﬁcantly
different from vehicle control. (b) In vitro scratch wound healing assay in H1581P, H1581AR and H1581BR cells. Representative images taken at
the indicated time points post-wounding are shown. (c) H1581P, H1581AR and H1581BR cell extracts were immunoblotted to detect indicated
proteins. Data shown in (a) are the mean± s.d. of three independent trials.
Figure 6. Inhibition of Met restores sensitivity to FGFR-TKIs. (a) H1581AR and H1581BR cells were treated with the indicated combinations of
the FGFR-TKIs, AZD4547 (AZD) and BAY1163877 (BAY), along with crizotinib (CRI) for the indicated time and cell viability was analyzed using
the MTT and clonogenic assays. (b) H1581AR and H1581BR cells were treated with either AZD4547 or BAY1163877 (0.1 μM) alone, or crizotinib
(0.2 μM) alone or with the combination of AZD or BAY with crizotinib for 2 h. Cell extracts were immunoblotted to detect the indicated
proteins. (c) H1581AR and H1581BR cells were treated with the indicated combinations of the Met inhibitor, SU11274, for the indicated time
and cell viability was analyzed using the MTT assay.
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for the ﬁrst time, that enhanced Met signaling by gene
ampliﬁcation or overexpression confers acquired resistance to
FGFR-TKIs. Notably, MET ampliﬁcation-driven ErbB3 activation
reactivated PI3K/AKT signaling, allowing H1581AR cells to bypass
the growth-inhibitory effects of AZD4547. Our data provided
preclinical evidence supporting a rationale for combined inhibi-
tion of FGFR and Met signaling to overcome acquired resistance to
FGFR-TKIs for the treatment of LC.
FGFR1 ampliﬁcation has been considered as a novel druggable
target in LC. Preclinical studies clearly demonstrated that FGFR1
ampliﬁcation confers dependence on FGFR signaling.4 Inhibition
of FGFR1 in both FGFR1-ampliﬁed LC cell lines and xenograft
models resulted in growth inhibition and apoptosis. These
promising preclinical results provided the rationale for clinical
studies of BGJ398 and AZD4547 for patients with FGFR1-ampliﬁed
LC. However, the clinical results of these selective FGFR-TKIs were
somewhat disappointing with overall responses of ~ 10%.11
Therefore, the therapeutic potential of FGFR inhibition in FGFR1-
ampliﬁed LC will remain uncertain until more comprehensive
understanding of FGFR pathway addiction is achieved.
The majority of LC cell lines tested in our study were resistant to
AZD4547 and BAY1163877, presumably reﬂecting the recent
disappointing clinical outcomes with selective FGFR-TKIs in LC
patients. Notably, of the ﬁve FGFR1-ampliﬁed cell lines, only two
(H1581 and DMS114) cell lines that express high mRNA and
protein level of FGFR1 were sensitive to these agents. Recently,
BGJ398-insensitive cells (NCI-H1703, HCC95 and Calu-3) were
shown to express low mRNA and protein level of FGFR1 even in
the presence of FGFR1 ampliﬁcation, indicting that both FGFR1
ampliﬁcation and protein overexpression are required for the
efﬁcacy of FGFR-TKI in LC.24 Moreover, FGFR1 mRNA and protein
expression, rather than FGFR1 ampliﬁcation, was also reported to
predict sensitivity to FGFR-TKIs in LC and head and neck
squamous cell carcinoma.25,26
Resistance to FGFR-TKIs in FGFR1-ampliﬁed cells can be driven
by multiple factors. First, FGFR1 ampliﬁcation is not necessarily
associated with mRNA and protein overexpression of FGFR1,
which, in turn, is more likely to activate FGFR pathway. For
example, HCC95, a squamous cell LC cell line, showed low mRNA
and protein expression of FGFR1 in the presence of FGFR1
ampliﬁcation at the genomic level (Supplementary Table 1).
Second, there may be a marked genomic heterogeneity in the
8p11-12 FGFR1 amplicon structure between sensitive (focal) versus
resistant (broad) cells, and the inﬂuence of these differences on
the degree of FGFR addiction is unknown.6 Finally, FGFR inhibitor-
resistant H1703 cell line carrying a focal FGFR1 ampliﬁcation has
been shown not to be dependent on FGFR1 but on ampliﬁed
platelet-derived growth factor receptor-α.21,24,27 This observation
suggests that co-occurrence of other activating oncogenes may
relieve FGFR1 dependence, resulting in the primary resistance to
FGFR inhibition. Moreover, our data show that is a correlation
between Met expression and the response to the FGFR inhibitors,
indicating that Met may have a role in de novo resistance to FGFR
inhibitors (Supplementary Figure 1b, lower panel).
In our study, high basal level of FRS2/PLC-γ was observed only
in FGFR inhibitor-sensitive cell lines. Upon ligand binding,
subsequent downstream signaling occurs through two main
pathways via the FRS2 and PLC-γ, leading ultimately to activation
of MAPK and PI3K/AKT pathways.8 Similar to ours, an elevated
level of FRS2 phosphorylation was observed in H1581 cells
carrying focal FGFR1 ampliﬁcation, but not in cells harboring
relatively broader levels of FGFR1 ampliﬁcation.21 Also, phosphor-
ylation of ERK1/2 was inhibited only in FGFR inhibitor-sensitive cell
lines, indicating that the MAPK pathway is the major signaling
pathway engaged in FGFR-driven oncogenesis. Similarly, ERK1/2
phosphorylation was inhibited upon BGJ398 treatment in FGFR1
overexpressing BGJ398-sensitive cells.24
Little is known about the acquired resistance to FGFR-TKIs in LC.
In a recent report, Chell et al.28 established a KMS-11 myeloma cell
line carrying the FGFR3Y373C mutation with acquired resistance
to AZ8010, an FGFR inhibitor, and their sequencing analysis of
resistant cells revealed a point mutation at the gatekeeper residue
in FGFR3 (FGFR3V555M). The other mechanism of acquired
resistance, which involved ErbB2/3 activation in a rapid, reversible
and ligand-dependent manner, was observed in a study of
resistance to BGJ398 in the RT112 bladder cancer cell line.29 In this
study, total and p-Met were undetectable in the BGJ398-resistant
cells, in contrast to our ﬁndings of the exclusive activation of Met
signaling mediating ErbB3-dependent or -independent activation
of PI3K/AKT signaling seen in H1581AR and H1581BR cells.
Activation of alternative RTKs including Met mediates acquired
resistance to targeted therapies in various types of cancers by
maintaining the signaling of key downstream pathways.14 In our
study, we examined the mechanisms underlying acquired
resistance to an FGFR-TKIs and found Met overexpression in two
different drug-resistant cell lines, only one of which had MET
ampliﬁcation. Compared with sensitive cells, acquired resistant
cells (H1581AR and H1581BR) had overexpression and activation
of Met. In cells with acquired resistance, cell proliferation
underwent a dependency switch from predominantly the FGFR
to the Met pathway, suggesting that Met signaling can
compensate for FGFR inhibition. To the best of our knowledge,
ours is the ﬁrst report to date to demonstrate the association
between Met overexpression and acquired resistance to the FGFR-
TKIs in LC. Interestingly, quantitative PCR on genomic DNA and
FISH analysis conﬁrmed MET ampliﬁcation in H1581AR, but not in
H1581BR, cells. MET ampliﬁcation led to acquired resistance to
AZD4547 in H1581AR, through activation of ErbB3. Similar to our
ﬁndings, MET ampliﬁcation activates causes acquired resistance
to geﬁtinib by activating EGFR-independent phosphorylation
of ErbB3 in EGFR-mutant LC.17 We showed that active ErbB3
co-precipitates with p85 in a Met-dependent manner in
MET-ampliﬁed H1581AR, but not in H1581BR, cells. We interpret
the differences in the signaling complexes and cellular behavior of
the two drug-resistant LC cell lines as an indication of the different
cellular mechanisms subsumed to drive drug resistance, based on
the level of MET ampliﬁcation and/or Met overexpression.
Furthermore, acquired TKI resistance was characterized by EMT,
concomitant with Met activation. Importantly, combined treat-
ment of FGFR-TKI with crizotinib or Met-speciﬁc siRNA synergis-
tically inhibited cell proliferation in both H1581AR and H1581BR
cells. As shown in Figure 6, the stronger activity of crizotinib is
observed in BR cells, which do not show MET ampliﬁcation/
overexpression, whereas AZD-resistant cells that have MET
ampliﬁcation/expression show less sensitivity to crizotinib. We
examined other commercially available Met inhibitor (SU11274)
on the FGFR inhibitor-resistant cell lines (H1581AR or H1581BR) for
cell viability analysis. Met inhibitor (SU11274) showed similar
effect with that of crizotinib.
In conclusion, our ﬁndings suggest that Met activation is
sufﬁcient to bypass dependency on FGFR signaling and con-
current inhibition of these two pathways may be desirable to
overcome acquired resistance to FGFR-TKIs in LC. Our data provide
insight into a potential avenue for effective therapy of human
cancers with acquired resistance to FGFR-targeted therapy.
MATERIALS AND METHODS
Cell culture and reagents
Twenty-four cell lines were purchased from American Type Culture
Collection (ATCC). All cell lines were cultured in RPMI-1640; except
H1581 cells were cultured in Dulbecco's Modiﬁed Eagle's Medium (DMEM)
and Ham's F12 Nutrient Mixture (DME/F12; Invitrogen, Carlsbad, CA, USA).
Human bronchial epithelial BEAS2B cells were cultured in supplemented
keratinocyte growth medium (KGM) bullet kit medium (Lonza, Walkersville,
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MD, USA). AZD4547 and crizotinib were purchased from Sellekchem
(Houston, TX, USA). BAY1163877 was a gift from Bayer Healthcare AG
(Wuppertal, Germany)
Generation of inhibitor-resistant cell lines
AZD4547-resistant (AR) and BAY1163877-resistant (BR) derivatives of
H1581 cells were generated by exposing cells to stepwise increasing
concentrations (up to 1 μM) of each inhibitor. During generation of
resistant cell lines, H1581P cells were cultivated in the absence of DMSO.
The stepwise exposure to increasing drug concentrations was carried out
over ~ 4 months, after which time the IC50 concentrations were re-assessed
in each resistant cell line. Cells were then maintained continuously in the
presence of inhibitors at these new IC50 concentrations for a further
6 months.
MTT assay
Cells (3000 cells/well) were seeded on 96-well plates at 37 °C. After
overnight incubation, the cells were treated with the inhibitor for 72 h.
Then, MTT reagent [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-
bromide] was added to each well and incubated for 4 h at 37 °C. MTT
solubilization solution/stop mix (Promega, Madison, WI, USA) was added to
each well, mixed, and the plates were incubated overnight at 37 °C. After
measuring the absorbance at 570 nm, the data were graphically displayed
using GraphPad Prism version 5.0 for Windows (GraphPad Software Inc.,
San Diego, CA, USA).
Clonogenic assay
Cells (3000 cells/well) were plated onto 6-well plates, incubated overnight
at 37 °C, and then treated with indicated concentrations of inhibitor for
10 days. Colonies were ﬁxed with paraformaldehyde (4%) and stained with
crystal violet (0.05% w/v) for 30 min, after which time residual staining
solution was removed and plates were washed with water.
Immunoblotting and RTK array
Following treatment with drugs and/or siRNA, cells were lysed in lysis
buffer (Cell Signaling Technologies, Beverly, MA, USA). Total cell lysates
(20 μl/lane) were resolved by SDS–PAGE and blotted onto Immobilon-P
membranes (Millipore, Volketswil, Switzerland). Primary antibodies speciﬁc
for FGFR1, p-Met (Tyr1349), p-Met (Tyr1234/1235), Met, p-ErbB3 (Tyr1197),
ErbB3, p-FRS2α (Tyr436), p-AKT (Ser473), AKT, p-ERK1/2 (T202/Y204),
ERK1/2, p-STAT3 (Tyr705), STAT3, p-PLCγ (Τyr783), PLCγ, p-PKCδ (Ser660),
PKCδ, E-cadherin and vimentin were purchased from Cell Signaling
Technologies. Antibodies speciﬁc for FGFR2, FGFR3, FRS2, N-cadherin and
β-actin were purchased from Santa Cruz (Santa Cruz, CA, USA). Human RTK
arrays (R&D Systems, Minneapolis, MN, USA) were performed according to
the manufacturer's instructions.
Gene expression or GSEA
Quantitative analysis of RNA expression was performed using Illumina
HumanHT-12v4 gene chip cDNA microarrays (Illumina, San Diego, CA,
USA). Microarray data in the CEL format were normalized using the robust
multiple array average normalization method. GSEA was performed using
gene sets from the Molecular Signatures Database (MSigDB-C2 v4, Broad
Institute, Cambridge, MO, USA).
Quantitative RT–PCR
Total RNA was reverse-transcribed with the Superscript cDNA Synthesis Kit
(Invitrogen). Real-time PCRs were carried out in triplicate for each sample
using primers and TaqMan probes purchased from Applied Biosystems.
Reactions were run on a StepOnePlus system (Applied Biosystems, Foster
City, CA, USA) and were analyzed using the StepOne software version 2.3
(Applied Biosystems) for Windows. The relative expression level of each
gene was determined by the ΔΔCt method. Expression of MET
(Hs01565584_m1) was expressed relative to the mean of the endogenous
control, GAPDH (Hs02758991_g1).
MET copy number variation analysis
Total genomic DNA was puriﬁed from cells using gDNA MiniPrep kits
(Intron, Seoul, Korea). Real-time PCRs were carried out in triplicate for each
sample using primers and TaqMan probes purchased from Applied
Biosystems. Reactions were run on a StepOnePlus system (Applied
Biosystems) and were analyzed using the StepOne software version 2.3
for Windows. The relative expression level of each gene was determined
by the ΔΔCt method. Genomic levels of MET (Hs05018546_cn) were
expressed relative to the mean of the endogenous control, LINE1
(Hs01098704_cn).
FISH analysis
FISH assay was performed using MET-probe with Spectrum Orange (red)
and CEP8 with Spectrum Green (Abbott Molecular, Des Plaines, IL, USA)
following routine methods. FISH patterns were deﬁned and described in
previous studies.4 Cases were considered as MET positive (‘ampliﬁed’)
under one of the following conditions: the MET/CEP8 ratio ⩾ 2.0; the
average number of MET signals per tumor cell nucleus is ⩾ 6; the
percentage of tumor cells containing ⩾ 15 MET signals or large clusters is
⩾ 10%; or the percentage of tumor cells containing ⩾ 5 MET signals
is ⩾ 50%.
Transfection of siRNAs
siRNAs against Met were synthesized by IDT (the sequence of siRNA listed
in Supplementary Table 6) and a control siRNA was purchased from
Invitrogen. Cells were transfected with siRNA (10 nM ﬁnal concentration) for
48 h using Lipofectamine RNAiMax (Invitrogen) according to the
manufacturer’s instructions and then treated with the indicated drugs.
MET overexpression by lentiviral infection
H1581 cells overexpressing MET were established by lentiviral infection
and selection. 293FT cells were co-transfected using Lipofectamine 2000
(Life Technologies, Gaithersburg, MD, USA) with lentivirus packaging
plasmid and a MET expression plasmid (Addgene 37560) or pLenti CMV
GFP Puro (Addgene 17448). Forty-eight hours after transfection, viral
supernatants were collected for viral infection, and infected H1581 cells
were selected using puromycin (1 μg/ml) for 2 days.30
Immunoprecipitation
For the detection of Met/ErbB3 complexes, whole-cell lysates (1 mg) in cell
lysis buffer (Cell Signaling) were incubated with Protein A/G PLUS-Agarose
beads pre-conjugated with Met or ErbB3. Immunoprecipitates were
washed in lysis buffer, boiled in 2 × IP sample buffer, and analyzed by
immunoblotting using antibodies speciﬁc to the indicated proteins.
Statistical analysis
All numeric values are represented as the mean± s.d. Statistical
signiﬁcance of the data was determined using the Student’s unpaired
t-test. Values of P⩽ 0.05 were considered as statistically signiﬁcant.
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